{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-025648","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.369865+00:00","generated_at":"2026-06-22T10:21:33.859209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mesa Labs Q2 revenue up 64% but GAAP EPS down 65%; non-GAAP AOI up 55%","bullets":["Revenue $58.7M (+64% YoY); organic growth 12% (18% constant currency). Net income $1.3M (-65%), diluted EPS $0.24.","GAAP operating income $4.0M (-5%); non-GAAP AOI $15.5M (+55%), $2.88 per diluted share.","Segments: Clinical Genomics $18.4M (+27% seq), Sterilization $17.0M (+21% org), Biopharma $12.1M (+15% org), Calibration $11.2M flat.","H1 revenue $109.2M (+54%); GAAP operating loss $0.6M, net loss $0.1M; non-GAAP AOI $21.6M (+13%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-025648","json":"https://secwatch.observer/filing/0001437749-22-025648.json","markdown":"https://secwatch.observer/filing/0001437749-22-025648.md","text":"https://secwatch.observer/filing/0001437749-22-025648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774922025648/0001437749-22-025648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774922025648/mlab20221102_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:21:33.859209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d70032b8792ce6df78cb0508d9c77830831c6deb","claim":"MESA LABORATORIES INC /CO/ reported three and six months ended September 30, 2022 results: revenue $58,749, net income $1,306, EPS $0.24 per diluted share.","evidence_excerpt":"In comparison to the same quarter in the prior year (“2Q22”), revenues increased 64% to $58,749, operating income decreased 5% to $3,995 and net income was $1,306, a decrease of 65% or $0.24 per diluted share of common stock.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774922025648/0001437749-22-025648-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended September 30, 2022"},{"label":"Revenue","value":"$58,749"},{"label":"Net income","value":"$1,306"},{"label":"EPS","value":"$0.24 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}